Camilla Soenderby

Ms. Camilla Soenderby brings 25 years of international leadership experience from executive roles at leading biopharma organizations across the EU, US, and Asia. She formerly served as a corporate officer at Takeda, where she led global portfolio commercialization and commercial excellence, overseeing global brands with annual revenue of USD 13 billion. Prior to that, she worked as SVP, Head of Global Product Strategy for Shire, having previously held regional- and general management positions at Roche Pharma, Abbott (now AbbVie) and Schering Plough (now Merck & Co), and began her career as a management consultant at McKinsey and Company. Ms. Soenderby currently serves on the Boards of Directors of BB Biotech AG, Abivax S.A. and F2G Ltd, and is a member of the Novo Advisory Group at Novo Holdings and an Industrial Advisor to EQT.